Reading LRMR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LRMR free→Reading LRMR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LRMR free→QuarterlyIQ Insights · LRMR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 14, 2026, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the first quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed…
Results of Operations and Financial Condition. On March 19, 2026, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the fourth quarter of 2025 and for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be fur…
Entry into a Material Definitive Agreement. On February 25, 2026, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 20,000,000 shares (the “ Firm Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”), of t…
Unregistered Sales of Equity Securities. On January 21, 2026, Larimar Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Blue Owl Healthcare Opportunities IV Public Investments LP (the “Stockholder”), pursuant to which the Stockholder exchanged 2,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for 250,000 shares of Series A convertible preferred stock, a “toothless” preferred stock, par value $0.…
Results of Operations and Financial Condition. On January 12, 2026, Larimar Therapeutics, Inc. (the “ Company ”) disclosed in an updated slide presentation, posted on its website, that, as of December 31, 2025, the Company had approximately $136.9 million of cash, cash equivalents and marketable securities. The Company has not yet completed its quarter-end or year-end financial close processes for the quarter and year ended December 31, 2025. This unaudited, preliminary amount has been prepar…
Unregistered Sales of Equity Securities. On December 16, 2025, Larimar Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Blue Owl Healthcare Opportunities IV Public Investments LP (the “Stockholder”), pursuant to which the Stockholder exchanged 2,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for 250,000 shares of newly designated Series A convertible preferred stock, a “toothless” preferred st…
Results of Operations and Financial Condition. On November 5, 2025, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the third quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be…
Results of Operations and Financial Condition. On August 14, 2025, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the second quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deem…
Entry into a Material Definitive Agreement. On July 29, 2025, Larimar Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 18,750,000 shares (the “ Firm Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”), of the Company…
Results of Operations and Financial Condition. On July 29, 2025, Larimar Therapeutics, Inc. (the “ Company ”) announced in a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) of the Securities Act of 1933, as amended (the “ Securities Act ”), that, as of June 30, 2025, the Company had approximately $138.5 million of cash, cash equivalents and marketable securities. The Company has not yet completed its quarter-end financial close processes for the quarter ended June 30, 2025.…
Results of Operations and Financial Condition. On April 30, 2025, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the first quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purp…
Results of Operations and Financial Condition. On March 24, 2025, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the fourth quarter of 2024 and for the year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be fur…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 22, 2025, the Compensation Committee of the Board of Directors (the “ Compensation Committee ”) of Larimar Therapeutics, Inc. (the “ Company ”) and the Board of Directors, as applicable, granted performance-based restricted stock units (“ PSUs ”) to Carole S. Ben-Maimon, M.D., the Company’s President and Chief Executive Officer, Michael…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.